What are the recommended medications for managing myelodysplastic syndrome (MDS) based on risk category?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medication for Myelodysplastic Syndrome (MDS)

Treatment for MDS is fundamentally determined by risk stratification: for higher-risk MDS, azacitidine is the standard of care to prolong survival; for lower-risk MDS, treatment targets specific cytopenias with erythropoiesis-stimulating agents (ESAs) as first-line for anemia without del(5q), lenalidomide for del(5q)-associated anemia, and luspatercept after ESA failure in patients with ring sideroblasts. 1

Treatment Algorithm by Risk Category

Higher-Risk MDS

Primary therapy:

  • Azacitidine is the recommended first-line treatment for patients without major comorbidities who are not immediately eligible for allogeneic stem cell transplantation (allo-SCT) 1, 2
  • AML-like chemotherapy is reserved for fit patients (generally <70 years) with favorable cytogenetics and marrow blasts ≥10%, preferably as a bridge to allo-SCT 1
  • Allo-SCT should be offered to all higher-risk patients <70 years without major comorbidities who have a donor, as this remains the only curative approach 1, 3

Alternative options:

  • Decitabine or oral decitabine/cedazuridine 2
  • For patients with IDH1 mutations: ivosidenib or olutasidenib (category 2B) 2

Important caveat: Combination therapies with hypomethylating agents have not proven superior to azacitidine monotherapy in clinical trials 3, 4, 5. The outcome after hypomethylating agent failure remains poor with no approved interventions 3, 6.

Lower-Risk MDS

Treatment is tailored to the specific cytopenia and genetic features:

For Symptomatic Anemia WITHOUT del(5q):

  1. First-line: ESAs (especially EPO alpha) - highest efficacy when initiated before permanent transfusion dependence 1, 4
  2. After ESA failure in patients with ring sideroblasts (MDS-RS): Luspatercept 1
  3. After ESA failure in younger patients (<60 years) with <5% marrow blasts, hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones: Antithymocyte globulin (ATG) ± cyclosporine 1, 2
  4. Other second-line options: lenalidomide + ESA or hypomethylating agents (not approved in Europe for this indication) 1
  5. Imetelstat was approved in 2024 for transfusion-dependent lower-risk MDS 3

For Symptomatic Anemia WITH del(5q):

  • Lenalidomide is the most effective drug and is the preferred first-line treatment 1, 4
  • If serum erythropoietin (sEPO) ≤500 mU/mL: lenalidomide is preferred, but ESAs are also reasonable 2
  • If sEPO >500 mU/mL: lenalidomide is category 1 preferred (26.9% achieved RBC transfusion independence ≥8 weeks vs 9.1% placebo) 2

For Clinically Significant Thrombocytopenia or Neutropenia:

  • Clinical trial, azacitidine, decitabine, or oral decitabine/cedazuridine 2
  • Immunosuppressive therapy ± eltrombopag for select patients (generally <60 years, <5% marrow blasts) 2
  • TPO receptor agonists (romiplostim, eltrombopag) have efficacy in severe thrombocytopenia but are NOT approved for MDS and should only be used in patients with marrow blasts <5% 1

Supportive Care Considerations

Transfusion Management:

  • RBC transfusions should be administered at a threshold of at least 8 g/dL (9-10 g/dL with comorbidities or poor tolerance) 1
  • Transfuse sufficient RBC concentrates to increase hemoglobin above 10 g/dL to limit chronic anemia effects on quality of life 1

Iron Chelation:

Strongly recommended in:

  • All candidates for allo-SCT (even moderate iron overload increases transplant-related mortality) 1
  • Non-transplant candidates with lower-risk MDS who have major iron overload (significantly reduced cardiac T2* on MRI) 1

Consider starting when:

  • Patients have received 20-60 RBC concentrates, OR
  • Serum ferritin rises above 1000-2500 U/L 1

Agent selection:

  • Deferasirox (oral) is preferred for ease of administration 1
  • Deferoxamine (parenteral) is an alternative
  • Deferiprone is NOT approved for MDS in most countries due to risk of neutropenia 1
  • Contraindication: Deferasirox cannot be used in renal failure 1

Infection Management:

  • Prophylactic antibiotics and G-CSF are NOT recommended for neutropenia 1
  • Rapid initiation of broad-spectrum antibiotics is mandatory with fever or infection symptoms 1
  • Short-term G-CSF may be useful during severe infections in neutropenic patients 1

Critical Decision Points

When to escalate from lower-risk to higher-risk management:

  • If disease initially managed as lower-risk fails to respond, move to higher-risk strategies 2
  • IPSS-R Intermediate-Risk MDS with score ≤3.5 can be managed as lower-risk; score >3.5 should be managed as higher-risk 2

Common pitfall: Many clinicians delay ESA initiation until patients become transfusion-dependent. ESAs have better and more durable responses when started before permanent transfusion need develops 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.